Valuation: Celcuity Inc.

Market Cap 5.26B 4.6B 4.23B 3.94B 7.48B 501B 7.59B 50.77B 19.74B 246B 19.76B 19.34B 849B P/E 2026 *
-26.9x
P/E 2027 * -224x
Enterprise Value 5.26B 4.6B 4.23B 3.94B 7.48B 501B 7.59B 50.77B 19.74B 246B 19.76B 19.34B 849B EV / Sales 2026 *
125x
EV / Sales 2027 * 13.7x
Free-Float
89.97%
Yield 2026 *
-
Yield 2027 * -
1 day+3.31%
1 week+12.53%
Current month+3.18%
1 month+18.08%
3 months-4.16%
6 months+7.36%
Current year+8.23%
1 week 98.54
Extreme 98.54
108.32
1 month 82.55
Extreme 82.5536
108.32
Current year 82.55
Extreme 82.5536
151.02
1 year 13.14
Extreme 13.141
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 31/12/2011
Chief Executive Officer 64 31/12/2011
Director of Finance/CFO 59 30/06/2017
Director TitleAgeSince
Chairman 64 31/12/2011
Director/Board Member 64 31/12/2011
Director/Board Member 67 31/01/2014
Date Insider Type Main position Quantity % Market Cap.
06-09Don

Director

-25,006 0.0540%
06-09Don

Director

-28,096 0.0607%
06-04
Brightstone Venture Capital LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%+12.53%+727.84%+883.15% 5.26B
+0.68%+5.92%+80.45%+137.78% 58.73B
+2.32%+5.89%+76.81%+99.20% 53.92B
-10.61%+8.38%-9.90%-9.62% 24.67B
-0.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.47%+46.43%+0.03% 18.8B
-0.29%+9.78%+44.62%-27.94% 17.61B
0.00%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+20.94%+51.67% - 13.9B
Average +2.91%+7.70%+122.87%+228.86% 24.74B
Weighted average by Cap. +2.46%+5.68%+74.01%+155.14%

Financials

2026 *2027 *
Net sales 42.08M 36.78M 33.81M 31.51M 59.77M 4.01B 60.67M 406M 158M 1.97B 158M 155M 6.79B 383M 335M 308M 287M 544M 36.46B 552M 3.69B 1.44B 17.92B 1.44B 1.41B 61.76B
Net income -218M -190M -175M -163M -309M -20.73B -314M -2.1B -816M -10.19B -817M -800M -35.11B -34.95M -30.55M -28.08M -26.17M -49.64M -3.33B -50.39M -337M -131M -1.64B -131M -128M -5.64B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
02/07/26 US$107.95 +3.31% 1,044,326
01/07/26 US$104.49 -0.12% 1,098,150
30/06/26 US$104.62 +2.05% 1,088,291
29/06/26 US$102.52 +2.57% 1,032,384
26/06/26 US$99.95 +4.19% 2,565,086
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
107.95USD
Average target price
160.64USD
Spread / Average Target
+48.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock